This phase III trial is trying to find the best combination of cancer drugs (SAR439859 + palbociclib, compared to letrozole + palbociclib) to improve survival in patients with ER+, HER2- advanced breast cancer who have not received prior treatment for advanced disease.
This trial is treating patients with ER+, HER2- breast cancer.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease
Eligible patients will be randomised to receive a continuous dose of either SAR439859 or Letrozole once-daily, in combination with a dose of Palbociclib once daily on days 1-21 of every 28-day cycle. Goserelin may also be administered once every 4 weeks in pre/peri menopausal women and men.
Recruiting Hospitals Read More